Response to the letter: "Predictive factors for transition to conversion therapy in HCC using atezolizumab plus bevacizumab".
Kikuchi T, Takeuchi Y, Nouso K, Kariyama K, Kuwaki K, Toshimori J, Iwado S, Moriya A, Hagihara H, Takabatake H, Tada T, Yasunaka T, Sakata M, Sue M, Miyake N, Adachi T, Wada N, Onishi H, Shiraha H, Takaki A, Otsuka M.
Kikuchi T, et al. Among authors: hagihara h.
Liver Int. 2024 Jul;44(7):1736-1737. doi: 10.1111/liv.15964. Epub 2024 May 8.
Liver Int. 2024.
PMID: 38717049
No abstract available.